232 related articles for article (PubMed ID: 36154274)
21. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.
Sontag SJ; O'Connell S; Schnell T; Chejfec G; Seidel J; Sonnenberg A
Am J Gastroenterol; 2001 May; 96(5):1390-5. PubMed ID: 11374672
[TBL] [Abstract][Full Text] [Related]
22. A new look at anti-Helicobacter pylori therapy.
Chuah SK; Tsay FW; Hsu PI; Wu DC
World J Gastroenterol; 2011 Sep; 17(35):3971-5. PubMed ID: 22046084
[TBL] [Abstract][Full Text] [Related]
23. Helicobacter pylori and gastric or duodenal ulcer.
Prescrire Int; 2016 Jan; 25(167):18-23. PubMed ID: 26942258
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis.
Han Z; Li Y; Kong Q; Liu J; Wang J; Wan M; Lin M; Lin B; Zhang W; Ding Y; Wang S; Mu Y; Duan M; Zuo X; Li YQ
Helicobacter; 2022 Dec; 27(6):e12930. PubMed ID: 36156332
[TBL] [Abstract][Full Text] [Related]
25. First-line treatment of Helicobacter pylori in Lebanon: Comparison of bismuth-containing quadruple therapy versus 14-days sequential therapy.
Tarhini M; Fayyad-Kazan M; Fayyad-Kazan H; Mokbel M; Nasreddine M; Badran B; Kchour G
Microb Pathog; 2018 Apr; 117():23-26. PubMed ID: 29428426
[TBL] [Abstract][Full Text] [Related]
26. Role of bismuth in improving Helicobacter pylori eradication with triple therapy.
Dore MP; Lu H; Graham DY
Gut; 2016 May; 65(5):870-8. PubMed ID: 26848181
[TBL] [Abstract][Full Text] [Related]
27. Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments.
Neri M; Milano A; Laterza F; Di Bonaventura G; Piccolomini R; Caldarella MP; Balatsinou C; Lapenna D; Cuccurullo F
Aliment Pharmacol Ther; 2003 Oct; 18(8):821-7. PubMed ID: 14535876
[TBL] [Abstract][Full Text] [Related]
28. Practical Aspects in Choosing a Helicobacter pylori Therapy.
Molina-Infante J; Shiotani A
Gastroenterol Clin North Am; 2015 Sep; 44(3):519-35. PubMed ID: 26314666
[TBL] [Abstract][Full Text] [Related]
29. Toward population specific and personalized treatment of Helicobacter pylori infection.
Liou JM; Chen PY; Kuo YT; Wu MS;
J Biomed Sci; 2018 Oct; 25(1):70. PubMed ID: 30285834
[TBL] [Abstract][Full Text] [Related]
30. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
31.
Qu P; Liu X; Xia X; Xie X; Luo J; Cheng S; Chi J; Liu P; Li H; Zhao W; Yang H; Xu C
Front Cell Infect Microbiol; 2022; 12():903002. PubMed ID: 35880079
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China.
Zhou JJ; Shi X; Zheng SP; Tang D; Cai T; Yao Y; Wang F
Helicobacter; 2020 Dec; 25(6):e12755. PubMed ID: 32914914
[TBL] [Abstract][Full Text] [Related]
33. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy.
Phillips RH; Whitehead MW; Lacey S; Champion M; Thompson RP; Powell JJ
Helicobacter; 2000 Sep; 5(3):176-82. PubMed ID: 10971684
[TBL] [Abstract][Full Text] [Related]
34. Helicobacter pylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies.
Cosme A; Torrente Iranzo S; Montes Ros M; Fernández-Reyes Silvestre M; Alonso Galán H; Lizasoain J; Bujanda L
Helicobacter; 2019 Feb; 24(1):e12557. PubMed ID: 30460730
[TBL] [Abstract][Full Text] [Related]
35. Bismuth salts with versus without acid suppression for Helicobacter pylori infection: A transmission electron microscope study.
Chiang TH; Chen CC; Tseng PH; Liou JM; Wu MS; Shun CT; Lee YC; Graham DY
Helicobacter; 2021 Jun; 26(3):e12801. PubMed ID: 33740276
[TBL] [Abstract][Full Text] [Related]
36. High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study.
Poonyam P; Chotivitayatarakorn P; Vilaichone RK
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2859-2864. PubMed ID: 31554388
[TBL] [Abstract][Full Text] [Related]
37. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori.
Savarino V; Zentilin P; Pivari M; Bisso G; Raffaella Mele M; Bilardi C; Borro P; Dulbecco P; Tessieri L; Mansi C; Borgonovo G; De Salvo L; Vigneri S
Aliment Pharmacol Ther; 2000 Jul; 14(7):893-900. PubMed ID: 10886045
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycinresistant and- sensitive cases.
Aydin A; Onder GF; Akarca US; Tekin F; Tunçyürek M; Musoğlu A
Turk J Gastroenterol; 2005 Dec; 16(4):203-6. PubMed ID: 16547848
[TBL] [Abstract][Full Text] [Related]
39. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
40. The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults.
He C; Peng C; Wang H; Ouyang Y; Zhu Z; Shu X; Zhu Y; Lu N
Helicobacter; 2019 Aug; 24(4):e12590. PubMed ID: 31124220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
